Translate
Denali Therapeutics Inc
About
Denali Therapeutics Inc (NASDAQ:DNLI) — investor relations, events, news, and company updates on 6ix.
Latest News
Apr 20 2026
Orsini Selected as the Exclusive Specialty Pharmacy and Home Infusion Partner for Denali Therapeutics' AVLAYAH™ (tividenofusp alfa-eknm)
Apr 3 2026
Denali Therapeutics Regains Full Rights to Investigational Therapy DNL593 (PTV:PGRN) for GRN-related Frontotemporal Dementia (FTD-GRN)
Mar 25 2026
Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH™ (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II)
Feb 26 2026
Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
Feb 5 2026
Denali Therapeutics Presents Enzyme TransportVehicle™ Progress Across Three Clinical Programs for Treatment of Lysosomal Storage Disorders at 2026 WORLDSymposium™
Recent Videos
Denali’s Breakthrough Drug Could Unlock the Brain for Biologics
Apr 15, 2026
Denali’s Breakthrough Drug Could Unlock the Brain for Biologics
Apr 10, 2026
FDA Acceptance and Priority Review of Biologics License Application (BLA) for Tividenofusp Alfa
Apr 07, 2026
AVLAYAH (tividenofusp): the first enzyme replacement therapy to cross BBB and treat Hunter syndrome
Mar 31, 2026
Financials
Revenue
$0
Market Cap
$3.27 B
EPS
-2.97